-- 据彭博社周四援引知情人士报道，再生元制药公司（Regeneron Pharmaceuticals，股票代码：REGN）已与特朗普政府达成协议，降低部分美国民众的药品价格，并已获得一种基因疗法的批准，用于治疗一种罕见的耳聋症。 再生元是特朗普政府根据最惠国待遇政策要求，将美国药品价格与发达国家价格接轨的最后一家公司。 特朗普政府一直向大型制药公司施压，要求其签署价格协议，以提供折扣价格或将价格与国际市场接轨，换取关税豁免等优惠。 报道称，美国食品药品监督管理局（FDA）预计将批准该疗法用于治疗一种由基因突变引起的极其罕见的遗传性听力损失。 （市场动态新闻来源于与全球市场专业人士的对话。这些信息据信来自可靠来源，但可能包含传闻和推测。准确性无法保证。）
Price: $763.89, Change: $+17.31, Percent Change: +2.32%
Seatrium (SGX:5E2) completed the divestment of a fleet of 17 tugboats, according to a Monday filing with the Singapore Exchange.The divestment is expected to deliver over SG$50 million in annualized cost savings.Shares of the specialized engineering solutions company were down over 2% in Monday trading.
China Nuclear Engineering's (SHA:601611) attributable profit fell 36% to 1.32 billion yuan in 2025 from 2.06 billion yuan in 2024, according to a Saturday filing with the Shanghai bourse.Earnings per share at the nuclear power company decreased 37% to 0.36 yuan from 0.57 yuan in the previous year.Operating revenue declined 10% year over year to 101.9 billion yuan from 113.5 billion yuan.Shares decreased 2% during the midday break on Monday.
Inner Mongolia Junzheng Energy & Chemical's (SHA:601216) attributable profit rose 18% to 3.32 billion yuan in 2025 from 2.80 billion yuan in 2024, according to a Saturday filing with the Shanghai bourse.Earnings per share at the chemical manufacturer increased to 0.3932 yuan from 0.3323 yuan in the previous year.Operating revenue stayed flat at 25.2 billion yuan.Shares increased 4% during the midday break on Monday.